Peter Hecht
Peter Hecht
clinical data highest investors pleased programs support syndicate validate
The encouraging data from our clinical programs validate the support our investors have shown. We are very pleased to fortify our outstanding investor syndicate with new investors of the highest quality.
advance both capital clinical equity including novel phase pipeline
This significant infusion of equity capital will be utilized to advance our proprietary pipeline of novel therapeutics through clinical trials, including both MD-1100 and our Phase I cholesterol absorption inhibitor MD-0727.